{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:53Z","timestamp":1793048813195,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacl.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T21:20:09Z","timestamp":1682544009000},"page":"406-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-692X","authenticated-orcid":false,"given":"Thomas A.","family":"Prohaska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Karwatowska-Prokopczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-6614","authenticated-orcid":false,"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2023.04.007_bib0001","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Boren","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","article-title":"Broadening the scope of dyslipidemia therapy by targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)","volume":"43","author":"Ginsberg","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0003","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/hep.23593","article-title":"Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study","volume":"51","author":"Speliotes","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2023.04.007_bib0004","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.04.007_bib0005","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2023.04.007_bib0006","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2023.04.007_bib0007","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2023.04.007_bib0008","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2023.04.007_bib0009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0011","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1007\/s00261-020-02783-1","article-title":"Liver fat quantification: where do we stand?","volume":"45","author":"Starekova","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0012","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2023.04.007_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.05.018","article-title":"Lipolytic enzymes and free fatty acids at the endothelial interface","volume":"329","author":"Goldberg","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2023.04.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158414","article-title":"Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering","volume":"7","author":"Ramms","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacl.2023.04.007_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/j.2040-4603.2014.tb00548.x","article-title":"Energy metabolism in the liver","volume":"4","author":"Rui","year":"2014","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101115","article-title":"Hepatic lipid droplets: a balancing act between energy storage and metabolic dysfunction in NAFLD","volume":"50","author":"Mashek","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacl.2023.04.007_bib0017","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2000mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0018","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2023.04.007_bib0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacl.2022.02.003","article-title":"Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins","volume":"16","author":"Le","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2023.04.007_bib0020","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The dawn of a new era of targeted lipid-lowering therapies","volume":"43","author":"Tokgozoglu","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:37:52Z","timestamp":1761831472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287423000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1933287423000739"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.04.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}